AI moves from documentation to operating systems, capital scales proven platforms, and sensing gets continuous

Tandem and the VA Push Workflow AI Beyond Documentation

Tandem Health’s €86.5M raise is the clearest sign yet that the category is moving past ambient note capture into end-to-end workflow control. The company says the capital will fund expansion across Europe and the buildout of an AI-native “Clinic Operating System” covering pre-visit summaries, in-visit decision support, post-visit coding and documentation, plus triage, scheduling, communications, and care coordination. That is a materially broader wedge than scribe software: Tandem cites integrations with 130+ medical record systems, and says coding assistance and point-of-care decision support are certified under EU MDR Class IIa, giving it both workflow and clinical-assistance credibility.

The buyer-side proof point is the VA’s rollout of Knowtex. After an AI Tech Sprint that evaluated more than 150 solutions, the VA awarded a $15 million contract and moved from a 10-site pilot in October 2025 to deployment across all VA PACT primary care providers by June 2026, with expansion into select outpatient specialty care planned for summer 2026. Reported gains were operational: less after-hours charting, lower cognitive load, better coding and risk adjustment, and roughly 1–2 hours saved per clinician after hours in Kansas City.

The market is now being won by platforms that own structured outputs, EHR connectivity, and multiple workflow layers—not the cleanest note.

AI Infrastructure Capital Moves From Proof Points to Platform Scale

Transformation Capital closed an oversubscribed $850 million Fund IV, above its prior $800 million vehicle, with a mandate to back commercial-stage, AI-enabled healthcare companies that can prove clinical and financial outcomes. In the same week, Thatch raised $108 million in Series C at a $1 billion valuation after nearly 7x ARR growth and adoption by more than 5,000 employers, while Angle Health secured $600 million to expand its technology platform and care-navigation infrastructure across 47 states.

The signal here builds on the earlier shift toward outcome-backed operators and enterprise workflow infrastructure: capital is now concentrating one layer deeper, around the platforms that control benefits administration, underwriting, care navigation, and AI-enabled operating infrastructure. These are being treated less as adjacent point solutions and more as category-defining systems with measurable ROI.

For operators, the bar has moved from product adoption to provable budget impact. For vendors and investors, the next advantage sits with platforms that have durable distribution, deep integration, and control over multi-step workflows rather than standalone features.

BD’s Vmax 160 Pushes Automation Into Pharmacy Fulfillment

Fairview’s rollout of BD’s Vmax 160 pushes the workflow-control story into physical operations: the Minnesota health system is using the robot for centralized outpatient boxed-medication fulfillment across a network that processes about 20,000 prescriptions a week through 25 outpatient pharmacies and mail-order services. The system automates storage, tracking, replenishment, labeling, and dispensing support, with BD citing 3-second tote loading, 99.8% accuracy, cold-chain storage at 2–8°C, and expiry detection that blocks expired drugs.

The same control model is extending across revenue-cycle workflows already in motion. This week’s deployments added automation in eligibility and benefits verification, coding, claim scrubbing and submission, denial prediction, appeal drafting, payment posting, A/R follow-up, and pre-bill review, while Waystar also announced autonomous claim resolution and an expected roughly 25% reduction in review time. HFMA/Guidehouse found 85.8% of financial executives rank payer practices such as denials and underpayments among their top three RCM challenges, and 71.7% are prioritizing RCM technology investments.

The progression is clear: the buying shift is from software that assists staff to infrastructure that protects throughput and reimbursement. Vendors and investors should expect value to concentrate in platforms that own more workflow steps end to end and can prove operational and cash-flow impact, not just feature adoption.

Clinician Command Centers Take the Lead in Continuous Sensing

Wireless patches, a CE-marked in-ear EEG for Europe, ambient AI for remote rehab, and an AI cardiac monitoring launch in India push the story beyond last week’s device-plus-dashboard model. The new development is clinician-managed workflow control: the in-ear EEG supports multi-day, multi-night ambulatory monitoring at home for epilepsy and sleep use cases; iLive Connect combines a chest patch and wrist wearable to capture two-lead ECG, respiratory rate, SpO2, temperature, activity, and HRV, routing data to a medical command centre; and Dozee Pro Ex extends AI-assisted cardiac and vital-sign monitoring through central oversight and mobile apps for doctors and nurses. iLive also cited a 10-week observational study of 410+ patients with a reported 76% reduction in frequent hospitalizations, signaling that vendors are now selling intervention workflows, not just sensors.

That matters because competition is shifting from signal capture to operational control of triage, escalation, and reimbursable care pathways. CMS did expand technology-supported care through the ACCESS Model beginning in spring 2027, but the available materials do not show broad new national coverage for pulse oximetry, general cardiac monitoring, or remote rehab sensing; the clearest concrete update was home INR monitoring for defined warfarin patients. Commercialization is advancing faster than U.S. reimbursement, making Europe and India the nearer-term scale markets. For operators, procurement will increasingly favor command-center-ready platforms over standalone devices; for vendors and investors, defensibility now depends on multi-parameter analytics, regulatory traction, and proof that continuous sensing changes utilization.